

April 15, 2022

VIA EDGAR

United States Securities and Exchange Commission
Division of Corporation Finance
Mail Stop 4720
100 F Street, N.E.
Washington, D.C. 20549

Re: Edesa Biotech, Inc.
Registration Statement on Form S-1
File No. 333-264235
CIK No. 0001540159

Acceleration Request

Requested Date: April 19, 2022

Requested Time: 4:30 PM, Eastern Time

Dear Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Edesa Biotech, Inc. (the "Company") hereby requests that the above-referenced Registration Statement (the "Registration Statement") be declared effective by the Securities and Exchange Commission (the "Commission") at the "Requested Date" and "Requested Time" set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Commission.

Please call Steven M. Skolnick of Lowenstein Sandler LLP at (646) 414-6947 to confirm the effectiveness of the Registration Statement or with any questions.

Sincerely,

EDESA BIOTECH, INC.

By: /s/ Kathi Niffenegger

Name: Kathi Niffenegger

Title: Chief Financial Officer
